Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + cisplatin
- Development stage
- Unknown
- Lead developer
- Assertio
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Fluorouracil + cisplatin is a combination chemotherapy regimen consisting of the antimetabolite fluorouracil (5-FU) and the platinum-based alkylating agent cisplatin. In the context of the Japan Clinical Oncology Group (JCOG) 9907 trial, this regimen was evaluated as a neoadjuvant (preoperative) treatment for patients with stage II/III esophageal squamous cell carcinoma (ESCC). Fluorouracil acts by inhibiting thymidylate synthase, thereby interfering with DNA synthesis, while cisplatin forms DNA cross-links that impede DNA replication and transcription, leading to apoptosis. The JCOG9907 trial established neoadjuvant FP therapy followed by surgery as the standard of care in Japan for locally advanced ESCC after demonstrating superior overall survival compared to postoperative administration.
- Brand names
- AdrucilPlatinol
- Other names
- 5-FU + cisplatin5-fluorouracil + cisplatinJCOG9907 regimenJCOG-9907 regimenJCOG 9907 regimen
02
Targets
TS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + cisplatin.